Palatin Technologies

We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions. $PTN

[Palatin Technologies @PalatinTech]

Palatin to Begin Trading on Nasdaq Stock Exchange

Read the Full Press Release 👉 https://t.co/iN7F7QX7j7

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Read the Full Press Release 👉 https://t.co/aVyTYGNiEg

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Read the Full Press Release 👉 https://t.co/WsdS2xV9fm

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Read the Full Press Release 👉 https://t.co/1oZTMrRGFp

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option

Read the Full Press Release 👉 https://t.co/Zg9LjNlKQZ

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Read the Full Press Release 👉 https://t.co/H4GJRJQgnM

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

Read the Full Press Release 👉 https://t.co/M63xh1S5lE

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

Read the Full Press Release 👉 https://t.co/tWr0wF3sD8

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Read the Full Press Release 👉 https://t.co/CVDlygs84J

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

Palatin Announces 1-for-50 Reverse Stock Split

Read the Full Press Release 👉 https://t.co/simua1lgNc

#PTN #PTNT #NYSE #OTCQB #News

[Palatin Technologies @PalatinTech]

💡 Rapid & effective symptom relief for Dry Eye Disease is on the horizon! PL9643 is advancing through Phase 3 trials, bringing us closer to a new therapeutic option. Stay informed: https://t.co/G2R4Pj5Kr6

#EyeCare #Innovation #PalatinTech #DED

[Palatin Technologies @PalatinTech]

🚨 Breaking News 🚨: FDA confirms the acceptability of Palatin's Phase 3 trials for PL9643 in Dry Eye Disease! 🌟 Strong tolerability & safety profile. A major step forward in eye care innovation. Learn more: https://t.co/G2R4Pj5Kr6

#DryEyeDisease #ClinicalTrials #Biotech

[Palatin Technologies @PalatinTech]

This study aims to advance obesity treatment by combining our MCR4 agonists with incretin therapeutics. #ObesityTreatment #ClinicalTrials #Biotech #HealthcareInnovation

[Palatin Technologies @PalatinTech]

🚀 Palatin Technologies kicks off a Phase 2 obesity study w/ Bremelanotide & Tirzepatide. Learn more: https://t.co/JFEytJ2C9M

[Palatin Technologies @PalatinTech]

🔥 Breaking: Palatin Technologies $PTN reveals positive results from our Phase 3 trial of PL9643 for Dry Eye Disease at ASCRS 2024! 🌐 Quick relief & excellent safety. Dive into the future of eye care with us! 🚀 #EyeHealth #Biotech https://t.co/NRQbFw0Lls

[Palatin Technologies @PalatinTech]

$PTN Vyleesi® (bremelanotide injection) delivers its 7th consecutive quarter of double-digit growth in product revenue and prescriptions dispensed. Prescriptions grew 18% & net product revenue increased 14% over the prior quarter.  https://t.co/A70a30XhTU

[Palatin Technologies @PalatinTech]

We believe the MC4R agonist is the best validated mechanism for adjunctive therapy with GLP-1 agonists and weight loss maintenance. Read the full PR announcement https://t.co/hrYi35VJKH

[Palatin Technologies @PalatinTech]

With the increased use of FDA-approved GLP-1 agonists for treating obesity, there is an unmet need for treatments with alternative mechanisms of action that will help obese patients meet and maintain their weight loss objectives.

[Palatin Technologies @PalatinTech]

Excellent safety and tolerability product profile. Potential for PL9643 to address multiple signs and symptoms of dry eye disease.
Learn More: https://t.co/vSGowOa4YG

[Palatin Technologies @PalatinTech]

$PTNachieves complete enrollment in Palatin's Phase 3 MELODY-1 study of PL9643 for the treatment of patients with dry eye disease. Topline data is currently expected late 4Q calendar 2023. Interim analysis of the first 120 patients demonstrated: